Pharmaceuticals
Millions of Women who Suffer from Pelvic Pain Still Unaware of Pelvic Venous Congestion Syndrome PVCS
SYDNEY, Oct. 20, 2022 /PRNewswire/ -- Pelvic pain is a common condition
affecting millions of women around the world, with up to 40% affected during
their lifetime. Of those affected, 30% suffer from Pelvic Venous Congestion
Syndrome (PVCS). Boston Scientific haslaunched a new website
2022-10-20 10:00
1701
Telix Reports Third Quarter 2022 Financial Results
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise...
2022-10-20 06:09
1498
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®-- -- PTX-COVID19-B was well tolerated with no safety signals-- -- Everest is filing IND applications for phase 3 clinical trials for booster indication-- SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest...
2022-10-19 20:15
2047
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...
2022-10-19 20:00
1813
MedAlliance to be Acquired by Cordis
GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of$35M and upfront closing payment of$200M, regulatory achievement milestones of up to $125M ...
2022-10-19 08:00
1759
Rhovac board member resigns due to health reasons
LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons. Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I w...
2022-10-18 21:29
1249
Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment
Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in its Phase2a clinical t...
2022-10-18 19:30
1216
CSafe Continues Expansion of Its Temperature-Controlled Shipping Solutions Portfolio with Introduction of Advanced Reusable Pallet Shipper
Loaded with innovation and technology, CSafeAPS provides superior temperature control and the industry's only in-transit thermal capacity indicator MONROE, Ohio, Oct. 18, 2022 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping sol...
2022-10-18 19:00
1811
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...
2022-10-18 06:43
1352
Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022
Phase 1 biomarker data confirms proof of mechanism with dose-dependent and potent inhibition of alternative and terminal pathways with KP104 via dual-targeting mechanism Data demonstrated KP104 was safe and well tolerated, and supports further investigation of KP104 in Phase 2 clinical studies ...
2022-10-17 19:00
1492
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
* New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials * Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve ther...
2022-10-17 13:00
1607
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...
2022-10-17 08:00
3088
Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, Mass. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) has cleared t...
2022-10-17 07:31
1656
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...
2022-10-17 07:25
1398
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Oct. 14, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present ...
2022-10-14 08:00
2021
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
* The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary "Alex DTx Platform"[1] in partnership with Vicore Pharma * In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety were given the DTx * Safety, functionality, and user exper...
2022-10-13 14:39
1155
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor (EGFR) inhibi...
2022-10-13 09:00
1619
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion prote...
2022-10-13 08:00
3132
Dr Ivan Puah, Liposuction Doctor In Singapore, Shares The Secret To Achieving A Good Liposuction Result
Liposuction is more than just what meets the eye. It is a procedure that combines science and art. SINGAPORE, Oct. 12, 2022 /PRNewswire/ -- Liposuction continuously ranks as one of the most preferred fat removal options. Its efficacy, however, does not reflect the intricacies and complexiti...
2022-10-12 11:38
1607
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company fromKyoto University, today announced that they have signed a Memorandum of Under...
2022-10-12 09:00
1791
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
9822
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
6268
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5661
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
4606
